1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 1, 2009, Pages 326-333

  Quan, Haitian ^a   Liu, Houfu ^a   Li, Chuan ^a   Lou, Liguang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; COMBRETASTATIN A4; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG GLUCURONIDATION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BUTADIENES; CELL LINE, TUMOR; CYTOTOXINS; DRUG SYNERGISM; GROWTH INHIBITORS; HCT116 CELLS; HUMANS; KB CELLS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; STILBENES;

EID: 67649836777     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.153320     Document Type: Article

References (36)

1. Andrieux L, Langouët S, Fautrel A, Ezan F, Krauser JA, Savouret JF, Guengerich FP, Baffet G, and Guillouzo A (2004) Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes. Mol Pharmacol 65:934-943. (Pubitemid 38420499)
2. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, et al. (2005) Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 11:1527-1533. (Pubitemid 40315236)
3. Boersma MG, van der Woude H, Bogaards J, Boeren S, Vervoort J, Cnubben NH, van Iersel ML, van Bladeren PJ, and Rietjens IM (2002) Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 15:662-670. (Pubitemid 34535121)
4. Chaplin DJ, Pettit GR, and Hill SA (1999) Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195. (Pubitemid 29168237)
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, and Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834. (Pubitemid 27209705)
6. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105. (Pubitemid 30781561)
7. Dokladda K, Green KA, Pan DA, and Hardie DG (2005) PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett 579:236-240. (Pubitemid 40023402)
8. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632. (Pubitemid 28334795)
9. Feijoo C, Campbell DG, Jakes R, Goedert M, and Cuenda A (2005) Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J Cell Sci 118:397-408. (Pubitemid 40277351)
10. Grosios K, Holwell SE, McGown AT, Pettit GR, and Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327.
11. Grosios K, Loadman PM, Swaine DJ, Pettit GR, and Bibby MC (2000) Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229-233. (Pubitemid 30189759)
12. Kamakura S, Moriguchi T, and Nishida E (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274:26563-26571. (Pubitemid 129520095)
13. Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O, and Tozer G (2004) The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 165:1401-1411. (Pubitemid 39297744)
14. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW 3rd, Shnyder SD, Cooper PA, and Bibby MC (2004) Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 10:1446-1453.
15. Lieuvin A, Labbé JC, Dorée M, and Job D (1994) Intrinsic microtubule stability in interphase cells. J Cell Biol 124:985-996. (Pubitemid 24109400)
16. Lin HL, Chiou SH, Wu CW, Lin WB, Chen LH, Yang YP, Tsai ML, Uen YH, Liou JP, and Chi CW (2007) Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther 323:365-373. (Pubitemid 47443252)
17. Lohr JW, Willsky GR, and Acara MA (1998) Renal drug metabolism. Pharmacol Rev 50:107-141.
18. MacKeigan JP, Collins TS, and Ting JP (2000) MEK inhibition enhances paclitaxelinduced tumor apoptosis. J Biol Chem 275:38953-38956. (Pubitemid 32058904)
19. McGurk KA, Brierley CH, and Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012. (Pubitemid 28167722)
20. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
21. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, and Al-Katib AM (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8:2735-2741. (Pubitemid 34856363)
22. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, and Begent RH (2001) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 61:4716-4722. (Pubitemid 32691881)
23. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, and Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45:209-211. (Pubitemid 19062390)
24. Quan H, Xu Y, and Lou L (2008) p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer 122:1730-1737.
25. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, and Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822. (Pubitemid 46621828)
26. Shalli K, Brown I, Heys SD, and Schofield AC (2005) Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19:1299-1301. (Pubitemid 41113729)
27. Siemann DW, Mercer E, Lepler S, and Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6. (Pubitemid 34273190)
28. Stadheim TA, Xiao H, and Eastman A (2001) Inhibition of extracellular signalregulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine- treated ML-1 cells. Cancer Res 61:1533-1540. (Pubitemid 34292584)
29. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, et al. (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438. (Pubitemid 46621821)
30. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
31. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, and Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634. (Pubitemid 29160136)
32. Wang Y, Yin S, Blade K, Cooper G, Menick DR, and Cabral F (2006) Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistry 45:185-194. (Pubitemid 43054096)
33. Wehbe H, Kearney CM, and Pinney KG (2005) Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res 25:3865-3870. (Pubitemid 41665156)
34. Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331.
35. Yuan LL, Chen X, Kunjilwar K, Pfaffinger P, and Johnston D (2006) Acceleration of K channel inactivation by MEK inhibitor U0126. Am J Physiol Cell Physiol 290:C165-C171.
36. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, et al. (2003) ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107:478-485. (Pubitemid 37266470)